Cardium Therapeutics Inc. CXM, Trading up 2.73% at Closed Market
Cardium Therapeutics Inc. CXM
Cardium Therapeutics today reported that a recent medical journal article highlights the challenges facing healthcare providers with respect to finding optimal treatments for patients with non-healing wounds.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to BOTTOM of this page for free stock alerts, or visit our site.
Cardium Therapeutics, Inc. focuses on the acquisition and development of innovative bio-medical product opportunities and businesses that have the potential to address unmet medical needs and definable pathways to commercialization, partnering, and other economic monetizations. The company’s investment portfolio includes the Tissue Repair Company and Cardium Biologics, which are medical technology companies primarily focused on the development of innovative therapeutic products for tissue repair and cardiovascular indications. Its products include Generx, a DNA-based growth factor therapeutic that is in Phase III clinical stage designed to leverage the body’s natural healing processes in response to repeated ischemic stress; Corgentin, a pre-clinical stage product, which enhances myocardial healing in and around the infarct zone when used as an adjunct to existing vascular-directed pharmacologic and interventional therapies; and Excellarate, a tissue repair’s product candidate that is in Phase IIb clinical trial for the treatment of non-healing diabetic foot ulcers. The company was founded in 2003 and is headquartered in San Diego, California.
About Stock Einstein StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
Thank you for your interest in Findit News. A member of the Findit News team will contact you soon to show you how you can take your marketing to the next level with press releases on Findit.
